Stay updated on Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial
Sign up to get notified when there's something new on the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page.

Latest updates to the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page
- Check2 days agoChange DetectedThe Taiwan site address now specifies Taoyuan City instead of Taoyuan, clarifying the city designation for the address while keeping the postal code 33305 the same.SummaryDifference0.0%

- Check9 days agoChange DetectedThe page revision tag was updated from v3.5.2 to v3.5.3, indicating a minor maintenance update to the page. There is no indication of changes to the study content or user-facing information.SummaryDifference0.0%

- Check16 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check38 days agoChange DetectedAdded the keyword Small cell lung carcinoma to the study metadata and included a resources entry for the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to the study content or layout.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed from the page.SummaryDifference0.0%

Stay in the know with updates to Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dinutuximab and Irinotecan vs Irinotecan in SCLC Clinical Trial page.